Study S000769

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06546384
Acronym: GLP-1 RA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 64
Start: 2026-11-01
Primary completion: 2026-12-31
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Conditions: Adiposity; Fatty Liver; Alcohol Use Disorder
Interventions: DRUG:Semaglutide; BEHAVIORAL:Weight reduction recommendations (nutritional and exercise)
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:2023

Registered primary outcomes

Proportion of patients achieving total alcohol abstinence (measured by negative PEth test) [From inclusion date (baseline) until end of the study, total duration 16 weeks per patient]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.